Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | APLNR | P35414 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10044898 | 0.87 | HDAC4 (0.58) | ALDH1A1KDM4EMEN1POLBPABPC1 | |
| SCHEMBL6994140 | 0.86 | KDM4E (0.59) | ALDH1A1KDM4EMEN1POLBPABPC1 | |
| SCHEMBL7598991 | 0.86 | ALDH1A1 (0.68) | ALDH1A1KDM4EMEN1POLBPABPC1 | |
| SCHEMBL10044901 | 0.85 | ALDH1A1 (0.67) | ALDH1A1KDM4EMEN1POLBPABPC1 | |
| SCHEMBL1685962 | 0.84 | ALDH1A1 (0.65) | ALDH1A1KDM4EMEN1POLBPABPC1 | |
| SCHEMBL7597398 | 0.84 | ALDH1A1 (0.65) | ALDH1A1KDM4EMEN1POLBPABPC1 | |
| SCHEMBL6997306 | 0.83 | HDAC4 (0.59) | ALDH1A1KDM4EMEN1POLBPABPC1 | |
| SCHEMBL30182558 | 0.83 | HDAC4 (0.59) | ALDH1A1KDM4EMEN1POLBPABPC1 | |
| SCHEMBL7826321 | 0.82 | HDAC4 (0.58) | ALDH1A1KDM4EMEN1POLBPABPC1 | |
| SCHEMBL7614893 | 0.82 | ALDH1A1 (0.62) | ALDH1A1KDM4EMEN1POLBPABPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117599201-B | Polypeptide coupling drug targeting M2 type macrophage and application thereof | 大连医科大学附属第一医院 | 2025-01-24 | — | — | CN | disclosed |
| CN-117599201-A | Polypeptide coupling drug targeting M2 type macrophage and application thereof | 大连医科大学附属第一医院 | 2024-02-27 | — | — | CN | disclosed |
| CN-117414438-A | Polypeptide coupling drug targeting M1 type macrophage and application thereof | 大连医科大学附属第一医院 | 2024-01-19 | — | — | CN | disclosed |
| CN-1157378-C | Quinoline derivs. | ��Ծ���＼������˾ | 2004-07-14 | — | — | CN | disclosed |
| EP-1095021-B1 | QUINOLINE DERIVATIVES | ACTIVE BIOTECH AB (SE) | 2003-09-17 | — | — | EP | disclosed |
| US-6605616-B1 | Autoimmune diseases; inflammation | ACTIVE BIOTECH AB (SE) | 2003-08-12 | — | — | US | disclosed |
| US-6593343-B2 | Quinoline derivatives | ACTIVE BIOTECH AB (SE) | 2003-07-15 | — | — | US | disclosed |
| EP-1073639-B1 | QUINOLINE DERIVATIVES | ACTIVE BIOTECH AB (SE) | 2002-11-27 | — | — | EP | disclosed |
| US-20020173520-A1 | Quinoline derivatives | ACTIVE BIOTECH AB (SE) | 2002-11-21 | — | — | US | disclosed |
| US-20020173519-A1 | Quinoline derivatives | ACTIVE BIOTECH AB (SE) | 2002-11-21 | — | — | US | disclosed |
| CN-1309641-A | Quinoline derivs. | ACTIVE BIOTECH AB (SE) | 2001-08-22 | — | — | CN | disclosed |
| EP-1095021-A1 | QUINOLINE DERIVATIVES | Active Biotech AB (SE) | 2001-05-02 | — | — | EP | disclosed |
| EP-1073639-A1 | QUINOLINE DERIVATIVES | Active Biotech AB (SE) | 2001-02-07 | — | — | EP | disclosed |
| US-6133285-A | 1-METHYL-2-OXO-3-N-PHENYL-N-METHYLAMINOCARBONYL-4-HYDROXY-1,2 -DIHYDRO-QUINOLINES; AUTOIMMUNE DISEASE AND PATHOLOGICAL INFLAMMATION, E.G., ASTHMA, ATHEROSCLEROSIS, STROKE AND ALZHEIMER'S DISEASE AND, ESPECIALLY, MULTIPLE SCLEROSIS | ACTIVE BIOTECH AB (SE) | 2000-10-17 | — | — | US | disclosed |
| US-6077851-A | USED FOR TREATMENT OF DISEASES RESULTING FROM AUTOIMMUNITY SUCH AS MULTIPLE SCLEROSIS, INSULIN-DEPENDENT DIABETES MELLITUS, SYSTEMIC LUPUS ERYTHEMATOSUS, RHEUMATOID ARTHRITIS, INFAMMATORY BOWEL DISEASE AND PSORIASIS; LAQUINIMOD AS NEW CHEMICAL ENTITY | ACTIVE BIOTECH AB (SE) | 2000-06-20 | — | — | US | disclosed |
| WO-2000003991-A1 | QUINOLINE DERIVATIVES | ACTIVE BIOTECH AB (SE) | 2000-01-27 | — | — | WO | disclosed |
| WO-1999055678-A1 | QUINOLINE DERIVATIVES | ACTIVE BIOTECH AB (SE) | 1999-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173520-A1 | Quinoline derivatives | CYP4F3, IRF3, CXCR3 | ALDH1A1 3735/4885KDM4E 1426/4885MEN1 1051/4885 |
| US-20020173519-A1 | Quinoline derivatives | CASP1, NFKBIA, IL1B | ALDH1A1 832/4885KDM4E 3654/4885MEN1 1499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.